Biologics Contract Manufacturing Market Segments by Application 2030

Biologics Contract Manufacturing Market Growth & Trends

The global biologics contract manufacturing market size is expected to reach USD 34.7 billion by 2030, registering a CAGR of 10.5% over the forecast period, according to a new report by Grand View Research, Inc. The global market was growing efficiently during the COVID-19 pandemic. This is due to a rise in R&D activities for the development of COVID-19 vaccines. In addition, there has been an expansion in manufacturing facilities to control the spread of the disease. For instance, in November 2021, Lonza announced that it has decided to expand its microbial development laboratories in Switzerland to support the company’s upcoming projects.

U.S. biologics contract manufacturing market size, by indication, 2020 - 2030 (USD Billion)

Biologics Contract Manufacturing Market Segmentation

Grand View Research has segmented the global biologics contract manufacturing market based on product, indication, and region:

Based on the Product Insights, the market is segmented into MABs, Recombinant Protein and Others.

  • The MABs segment dominated the global market in 2021 and accounted for the maximum share of more than 58.00%. The segment is projected to expand further at the fastest CAGR maintaining its leading position during the forecast period. The high growth of the segment can be attributed to the extensive usage of the products made by MABs in different therapeutic areas. The drugs produced by MABs are used for the treatment of cancer, chronic Hepatitis B (HBV) infection, infectious diseases, and autoimmune diseases including rheumatoid arthritis.

Based on the Indication Insights, the market is segmented into Oncology, Immunological Disorders, Cardiovascular Disorders (CVDs), Hematological Disorders, Others.

  • The oncology indication segment dominated the global market in 2021. The segment accounted for the largest share of more than 49.8% of the overall revenue in the same year. It is estimated to remain dominant throughout the forecast period. The segment growth can be attributed to the high costs of drug development, rising cancer cases, and FDA regulations to accelerate the biologics drug development.
  • On the other hand, the immunological disease segment is expected to witness the fastest CAGR over the forecast period. Biologics targeting autoimmune diseases have made a positive impact on the management of diseases, such as Rheumatoid Arthritis (RA), psoriasis, and other immunological disorders. Several biologics have been developed to attenuate common autoimmune diseases, and they target various pathological stages that occur during the development of immunological diseases.

Biologics Contract Manufacturing Regional Outlook

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Market Share Insights

  • November 2021: Lonza signed a five-year service agreement with Bioqube Ventures, a venture capital firm, wherein Lonza will provide development and manufacturing service of biologics and small molecules to the portfolio companies of Bioqube Ventures.

Key Companies Profile & Market Share Insights

Market players are undertaking various business strategies, such as forming alliances, to expand their geographical reach and capture a big market share. The key players are introducing advanced therapy and treatments to capture a big share in the market.

Some of the prominent players operating in the global biologics contract manufacturing market include,

  • Wuxi Biologics
  • Abzena Ltd.
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • Boehringer Ingelheim GmbH
  • Lonza
  • SamsungBiologics
  • Abbvie
  • Catalent
  • Bioreliance
  • Thermo Fischer (Patheon)
  • Eurofins CDMO

Order a free sample PDF of the Biologics Contract Manufacturing Market Intelligence Study, published by Grand View Research.

Comments

Popular posts from this blog

India Electric Vehicle Market Competitive Landscape Report to 2028

Cyber Security Market 2030 - Advanced Solutions for Modern Businesses

LiDAR Market Historical Data & Forecasts 2030